

# Helga Gardarsdottir

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/298463/helga-gardarsdottir-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87  
papers

1,110  
citations

17  
h-index

31  
g-index

93  
ext. papers

1,393  
ext. citations

3.9  
avg, IF

4.28  
L-index

#	Paper	IF	Citations
87	Indications for antidepressant drug prescribing in general practice in the Netherlands. <i>Journal of Affective Disorders</i> , <b>2007</b> , 98, 109-15	6.6	126
86	Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 849-57	2.8	110
85	Initiation of antidepressant therapy: do patients follow the GP's prescription?. <i>British Journal of General Practice</i> , <b>2009</b> , 59, 81-7	1.6	85
84	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 56-65	2.6	73
83	Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. <i>Journal of Clinical Epidemiology</i> , <b>2010</b> , 63, 422-7	5.7	69
82	The High Impact of Penicillin Allergy Registration in Hospitalized Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 926-31	5.4	65
81	Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases. <i>Calcified Tissue International</i> , <b>2014</b> , 94, 580-9	3.9	36
80	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. <i>Rheumatology</i> , <b>2016</b> , 55, 704-9	3.9	30
79	Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 66-78	2.6	30
78	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2524-2539	3.8	29
77	Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. <i>American Journal of Epidemiology</i> , <b>2009</b> , 170, 280-5	3.8	28
76	An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 7-15	2.6	28
75	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1150-1164	3.8	22
74	Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2006</b> , 15, 338-43	2.6	21
73	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 88-102	2.6	21
72	Does the length of the first antidepressant treatment episode influence risk and time to a second episode?. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 69-72	1.7	18
71	Redispensing of medicines unused by patients: a qualitative study among stakeholders. <i>International Journal of Clinical Pharmacy</i> , <b>2017</b> , 39, 196-204	2.3	17

70	The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. <i>Pharmaceutical Research</i> , <b>2018</b> , 35, 42	4.5	17
69	Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 114-21	2.6	16
68	Pharmacists' Activities to Reduce Medication Waste: An International Survey. <i>Pharmacy (Basel, Switzerland)</i> , <b>2018</b> , 6,	2	15
67	Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 1260-1269	1.2	15
66	Patient and medication factors associated with preventable medication waste and possibilities for redispensing. <i>International Journal of Clinical Pharmacy</i> , <b>2018</b> , 40, 704-711	2.3	14
65	Seasonal patterns of initiating antidepressant therapy in general practice in the Netherlands during 2002-2007. <i>Journal of Affective Disorders</i> , <b>2010</b> , 122, 208-12	6.6	14
64	Do patients initiate therapy? Primary non-adherence to statins and antidepressants in Iceland. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 597-603	2.9	12
63	Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study. <i>Drug Safety</i> , <b>2019</b> , 42, 887-895	5.1	12
62	Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 79-87	2.6	11
61	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. <i>Research in Social and Administrative Pharmacy</i> , <b>2019</b> , 15, 100-105	2.9	11
60	Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence. <i>Patient Preference and Adherence</i> , <b>2014</b> , 8, 179-90	2.4	10
59	Primary-care patients' trade-off preferences with regard to antidepressants. <i>Psychological Medicine</i> , <b>2014</b> , 44, 2301-8	6.9	10
58	Case-only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 103-13	2.6	10
57	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. <i>BMJ Open</i> , <b>2019</b> , 9, e024767	3	9
56	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 243	2.9	8
55	The association between patient-reported drug taking and gaps and overlaps in antidepressant drug dispensing. <i>Annals of Pharmacotherapy</i> , <b>2010</b> , 44, 1755-61	2.9	8
54	Older Patients' Compliance with Drug Storage Recommendations. <i>Drugs and Aging</i> , <b>2018</b> , 35, 233-241	4.7	6
53	Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda. <i>Malaria Journal</i> , <b>2019</b> , 18, 36	3.6	5

52	Associations Between Personality Traits and Adherence to Antidepressants Assessed Through Self-Report, Electronic Monitoring, and Pharmacy Dispensing Data: A Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 465-71	1.7	5
51	Transitions from General Practitioner to Psychiatrist Care (or vice versa) during a first antidepressant treatment episode. <i>Pharmacopsychiatry</i> , <b>2010</b> , 43, 179-83	2	5
50	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 122-31	2.6	5
49	Discontinuation of somatic medication during psychiatric hospitalization. <i>Annals of Pharmacotherapy</i> , <b>2014</b> , 48, 1415-24	2.9	4
48	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. <i>Cytotherapy</i> , <b>2020</b> , 22, 592-600	4.8	4
47	Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 594549	5.6	4
46	Actual versus recommended storage temperatures of oral anticancer medicines at patients' homes. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 382-389	1.7	4
45	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 1339-1352	2.6	4
44	Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA). <i>Drug Safety</i> , <b>2018</b> , 41, 871-880	5.1	3
43	Discontinuation of anticoagulant care during admission to a psychiatric hospital. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1025-9	2.8	3
42	Prevalence of medication use for somatic disease in institutionalized psychiatric patients. <i>Pharmacopsychiatry</i> , <b>2013</b> , 46, 274-80	2	3
41	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 154, 105501	5.1	3
40	Post-marketing dosing changes in the label of biologicals. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 715-721	3.8	3
39	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 988-1000	3.8	3
38	Medication Discontinuation in Patients After Discharge From a Psychiatric Hospital. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 1085-95	2.9	2
37	Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 111, 310	6.1	2
36	Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries. <i>Transfusion Medicine Reviews</i> , <b>2020</b> , 34, 94-100	7.4	2
35	Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF- $\alpha$ Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 123-131	6.1	2

34	Are Further Interventions Needed to Prevent and Manage Hospital-Acquired Hyponatraemia? A Nationwide Cross-Sectional Survey of IV Fluid Prescribing Practices. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
33	New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 960-974	2.6	2
32	Redispensing of unused HIV post-exposure prophylaxis for medical students. <i>Travel Medicine and Infectious Disease</i> , <b>2019</b> , 29, 82-83	8.4	2
31	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. <i>Biologicals</i> , <b>2021</b> , 69, 30-37	1.8	2
30	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	2
29	Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2018</b> , 8, 213-229	4.9	2
28	Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. <i>Drug Discovery Today</i> , <b>2021</b> ,	8.8	2
27	Distinct Profiles on Subjective and Objective Adherence Measures in Patients Prescribed Antidepressants. <i>Drugs</i> , <b>2019</b> , 79, 647-654	12.1	1
26	Quality of reporting of drug exposure in pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1141-1150	2.6	1
25	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. <i>Regenerative Medicine</i> , <b>2020</b> , 15, 1215-1227	2.5	1
24	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1563-1571	2.6	1
23	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. <i>Regenerative Medicine</i> , <b>2020</b> , 15, 2015-2028	2.5	1
22	Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	1
21	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3508-3517	3.8	1
20	COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 1517-1527	6.1	1
19	A systematic review of how missing data are handled and reported in multi-database pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 819-826	2.6	1
18	Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 1250-1256	6	1
17	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 128, 440-454	3.1	1

